Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bristol-Myers Squibb Co BMY

Healthcare
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule... see more

Recent & Breaking News (NYSE:BMY)

BMS and The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Program

Business Wire December 17, 2015

Bristol-Myers Squibb and UCLA Enter into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Research Program

Business Wire December 14, 2015

Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2015 on January 28

Business Wire December 11, 2015

AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism (VTE), VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Therapy

Business Wire December 10, 2015

Bristol-Myers Squibb Completes Previously Announced Acquisition of Cardioxyl Pharmaceuticals, Inc.

Business Wire December 8, 2015

Bristol-Myers Squibb Establishes Center for Molecular Synthesis in New Collaboration with Princeton University

Business Wire December 8, 2015

Bristol-Myers Squibb Announces Dividend Increase

Business Wire December 8, 2015

New Longer-Term Data for Empliciti (elotuzumab) Showed a Continued Progression-Free Survival Benefit in Patients with Relapsed or Refractory Multiple Myeloma

Business Wire December 5, 2015

Bristol-Myers Squibb Receives Multiple Myeloma Research Foundation's 2015 Collaborator Award

Business Wire December 4, 2015

Bristol-Myers Squibb Foundation Marks World AIDS Day with Grants Totaling More than $3.5M for HIV and Cervical and Breast Cancer Programs in Africa

Business Wire December 1, 2015

Bristol-Myers Squibb and AbbVie Receive FDA Approval of Empliciti(TM) (elotuzumab) for the Treatment of Patients with Multiple Myeloma Who Have Received One to Three Prior Therapies

Business Wire November 30, 2015

Bristol-Myers Squibb to Present New Data across Multiple Blood Cancers at the 57th Annual Meeting & Exposition of the American Society of Hematology

Business Wire November 30, 2015

Bristol-Myers Squibb Announces Regulatory Update for Opdivo (nivolumab) in Advanced Melanoma

Business Wire November 27, 2015

European Commission Approves Reconciliation of Indications for nivolumab Under the Opdivo® European Marketing Authorization Application

Business Wire November 24, 2015

Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma

Business Wire November 24, 2015

Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab), the Only Treatment to Deliver Significant Overall Survival in Advanced Renal Cell Carcinoma vs. a Standard of Care, in Patients Who Have Received Prior Anti-Angiogenic Therapy1

Business Wire November 23, 2015

New Long-Term Data on Opdivo and the Opdivo + Yervoy Regimen Shows Survival Benefit Across Lines of Therapy in Advanced Melanoma

Business Wire November 18, 2015

Data from ALLY-3+ Trial Investigating Daklinza (daclatasvir) in Combination with Sofosbuvir and Ribavirin in Chronic Hepatitis C Genotype 3 Patients with Advanced Fibrosis or Cirrhosis Presented at AASLD

Business Wire November 16, 2015

Bristol-Myers Squibb to Present New Data for Opdivo (nivolumab) in Advanced Melanoma, as Monotherapy and in Combination with Yervoy (ipilimumab), at the Society for Melanoma Research 2015 International Congress

Business Wire November 12, 2015

Bristol-Myers Squibb Foundation Awards Five Grants Totaling More than $2.77M to Programs Supporting Post-9/11 Military Veterans, their Families and Caregivers

Business Wire November 11, 2015